

# Losartan promotes cell survival following SARS-CoV-2 infection *in vitro*

Reza Nejat<sup>1, 2</sup>, Ahmad Shahir Sadr<sup>3, 4</sup>, Brendan T. Freitas<sup>5</sup>, Jackelyn Crabtree<sup>6</sup>, Scott D. Pegan<sup>5</sup>, Ralph A. Tripp<sup>6</sup>, David J. Najafi<sup>7, 8,\*</sup>

<sup>1</sup>Former Assistant Prof., Department of Anesthesiology and Critical Care Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

<sup>2</sup>Former ICU Chief, Bazarganan Hospital, Tehran, Iran.

<sup>3</sup>Bioinformatics Research Center, Cheragh Medical Institute and Hospital, Kabul, Afghanistan.

<sup>4</sup>Department of Computer and Data Sciences, Faculty of Mathematical Sciences, Shahid Beheshti University, Tehran, Iran.

<sup>5</sup>Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, Georgia 30602, United States

<sup>6</sup>Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, Georgia 30602, United States

<sup>7</sup>Former Assistant Clinical Professor, Shiley Eye Institute, UCSD, California 92037, USA.

<sup>8</sup>Founder and President of Alliance Retinal Consultants, La Mesa California 91942, USA.

**KEYWORDS:** Losartan, antiviral; COVID-19; severe acute respiratory syndrome; coronavirus; Vero E6; Ubiquitin; ISG15; inhibitor

## Abbreviations:

ACE, Angiotensin-Converting Enzyme; ACE2, Angiotensin-Converting Enzyme 2; AMC, C-terminal 7-amido-4-methylcoumarin; Ang I, Angiotensin I; Ang II, Angiotensin II; Ang (1-7), Angiotensin 1-7; Ang (1-9), Angiotensin 1-9; ARB, angiotensin receptor blockers; ARDS, acute respiratory distress syndrome; AT1R, Angiotensin II type 1 receptor; AT2R, Angiotensin II type 2 receptor; BSA, bovine serum albumin; CoV, coronavirus; COVID-19, coronavirus disease 2019; DMSO, dimethyl sulfoxide; DUB, deubiquitinase; GRL-0617, 5-amino-2-methyl-Nbenzamide; IL-6, interleukin-6; ISG15, interferon-stimulated gene product 15; MD, molecular dynamic; MERS-CoV, Middle East Respiratory Syndrome; NP, nuclear protein; NSP, nonstructural proteins; ORF1a/ORF1b, open reading frames; PLP, papain-like protease; PLpro, papain-like protease; proISG15, precursor ISG15; PRR, Pattern-Recognition Receptor; RAS, renin-angiotensin system; RBD, receptor binding domain; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TLR, Toll-like receptor; Tris, tris(hydroxymethyl)-aminomethane; Ub, ubiquitin; poly ub, polyubiquitin; UIM, ubiquitin interacting motif

---

\* Corresponding Author Email: [dnajafimd@gmail.com](mailto:dnajafimd@gmail.com)

**Warning:** This manuscript presents an in vitro study pending validation by clinical trials.

## Abstract

**Introduction:** Coronavirus disease 2019 (COVID-19) can be associated with mortality and high morbidity worldwide. There is an extensive effort to control infection and disease caused by SARS-CoV-2. This study addressed the hypothesis that angiotensin II type I receptor blocker, Losartan, may restrict pathogenesis caused by SARS-CoV-2 by decreasing viral-induced cytopathological changes by blocking angiotensin II type 1 receptor (AT1R), thus reducing the affinity of the virus for ACE2, and inhibiting papain-like protease of the virus.

**Method:** Losartan inhibitory effect on deubiquitination and deISGylation properties of papain-like protease was investigated using a fluorescence method and gel shift analysis determining its inhibitory effects.

The inhibitory effect of Losartan on SARS-CoV-2 cell replication was investigated both when losartan was added to the cell culture 1 hour before (pre-infection group) and 1 hour after (post-infection group) SARS-CoV-2 infection of Vero E6 cells.

**Results:** Losartan treatment of Vero E6 cells prior to and after SARS-CoV-2 infection reduced SARS-CoV-2 replication by 80% and 70% respectively. Losartan was not a strong deubiquitinase and deISGylase inhibitor of PLpro.

**Conclusion:** Losartan added pre- and post-infection to the Vero E6 cell culture significantly prevents cell destruction and replication by SARS-CoV2. Losartan has low side-effects, is readily available, and can be produced at high levels globally, all features of a promising drug in treatment of COVID-19 if validated by clinical trials.

## Introduction

The COVID-19 pandemic having with high morbidity and substantial mortality rates has created a global health and economic crisis since December of 2019. It is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is an enveloped non-segmented single-stranded positive sense RNA virus belonging to the beta-genus of the Orthocoronavirinae subfamily in the Coronaviridae family which includes SARS-CoV and Middle East Respiratory Syndrome CoV (MERS-CoV) [1, 2]. Since its emergence in Wuhan, China, SARS-CoV-2 has infected over 76 million and caused 1.7 million deaths globally according to the World Health Organization (WHO) status report on 23 of December 2020.

As a multi-organ disease, COVID-19 involves lungs, cardiovascular system, gastrointestinal tract and the central nervous system. This virus at the genomic level

has 79% homology with SARS-CoV [1-4]. There is currently no effective antiviral drug and currently developed vaccines are not expected to be administered worldwide by the end of 2021. Discovery of a drug that is globally available with antiviral properties and minimum side-effects would significantly impact the management of the pandemic.

SARS-CoV-2, like SARS-CoV, uses the ACE2 receptor, a member of renin-angiotensin system, to enter host cells [5]. Binding of the virus spike (S protein) protein, through its receptor binding domain (RBD) in S1 component to ACE2 mediates the cell entry [6]. Inhibition of this process halts infection and disease pathogenesis of COVID-19.

Entry of the virus into the host cell initiates its replication. Translation of two open reading frames, (ORF1a/ORF1b) produces two replicase polyproteins (pp1a/pp1ab) [7, 8]. These polyproteins each contain non-structural proteins (nsps) involved in viral replication. Cleavage of these replicases releases 16 nsps through an autoproteolyzing process. Sharing the first 11 nsps, pp1a and pp1ab release nsp1-11 and nsp1-16, respectively [9, 10]. Two cysteine proteases, papain-like protease (PLpro) and 3Chymotrypsin-like proteinase (3CLpro or Mpro), contribute to this proteolysis. PLpro is located in the sequence of nsp3 which separates nsp1/nsp2, nsp2/nsp3 and nsp3/nsp4 while Mpro, embedded in nsp5, separates the nsp4-11 of pp1a and nsp4-16 of pp1ab [10, 11]. Mpro has been shown to reduce induction of type I interferon [12]. In addition, PLpro of SARS-CoV-2, with 83% homology with its counterpart in SARS-CoV, has deubiquitinating and deISGylating potential with differing substrates. PLpro of SARS-CoV and SARS-CoV-2 show predominance in cleaving ubiquitin-like interferon-stimulated gene 15 (ISG15) proteins over poly-ubiquitin chains. However, SARS-CoV cleaves ubiquitin more readily than SARS-CoV-2 [13, 14]. These properties modify and suppress the repertoire of host cell proteins and mediators such as IFN- $\beta$ , ISG15 protein, IRF3, TLR3, TLR4, TLR7 and STING-mediated pathway engaged in innate immunity [14-21]. It is implied that both PLpro and Mpro influence the immunogenic molecular pathways which allows SARS-CoV-2 to evade recognition by innate immunity system which prolongs its incubation period in host cells.

PLpro, of SARS-CoV and SARS-CoV-2, cleaves nsp1, nsp2 and nsp3 at the **LXGG** sequence of their C-terminals. The **LXGG** is present in the C-terminus of ubiquitin and ISG15protein [22-24]. Therefore, iso- and endo-peptidase action of PLpro on suppression of SARS-Cov-2 is a desirable target to suppress its pathogenesis [22].

Inhibition of PLpro deubiquitinating and deISGylating action may prompt the innate immunity against the virus.

In the early months of 2020, angiotensin receptor blockers (ARBs) were noted to possibly provide protection against COVID-19 [25-27]. Stopping the use of ARBs was recommended in the early phase of the pandemic due to the concern over possible increase in viral load [28, 29]. Recent studies have revealed safety of ARBs in patients with COVID-19 [30, 31]. Importantly, a recent study proposed that Losartan, an ARB, could ameliorate complications, especially of acute respiratory distress syndrome (ARDS) associated with COVID-19 [27]. In a previous study, molecular dynamic (MD) analysis showed that Losartan could change the three-dimensional structure of ACE2, preventing establishment of strong bonds between RBD residues of the virus and the residues in ACE2 [27], and subsequently decrease the affinity of the virus to its receptor. Furthermore, the MD analysis showed that Losartan could change the conformational shape of PLpro by occupying the place for inhibitors of PLpro with high docking energy (Fig.6) [27]. This implies that Losartan may act as a PLpro inhibitor.

PLpro and PLP2 of other Coronaviruses have been shown to have a substantial impact on the pathogenesis of CoVs [32-35]. PLpro inhibitors in SARS-CoV-2, have shown to inhibit its replication through suppressing cleavage of nsps [36, 37]. Moreover, these inhibitors prevent PLpro from acting as a deubiquitinase (DUB) or deISGylase, the two properties that enable the virus to evade innate immunity [13, 14]. In addition, as ubiquitins are involved in normal regulatory cellular pathways, deubiquitinating activity of PLpro modifies the host cell environment promoting viral replication [38]. Further work on discoveries of noncovalent inhibitors of PLpro in 2008, which showed them to inhibit viral replication, was aborted soon [14, 39]. Here, we report the very weak inhibitory effect of Losartan against deubiquitinase and deISGylase properties of SARS-CoV-2 PLpro. In this *in vitro* study of Vero E6 cells, we show that adding Losartan pre- and post-infection with SARS-CoV2 considerably prevents viral replication.

## **Results:**

**Deubiquitinase and deISGylase inhibitory activity of Losartan on SARS-CoV-2 PLpro.** To characterize its inhibitory effects on SARS-CoV-2 PLpro,

Losartan was incubated at various concentrations with SARS-CoV-2 PLpro and a peptide substrate containing the last five consensus amino acids of ubiquitin (Ub) and interferon stimulated gene product 15 (ISG15) in conjugation with a C-terminal 7-amido-4-methylcoumarin (AMC) fluorogenic reporter group (peptide-AMC). These assays revealed  $IC_{50}$  value of  $1200 \pm 61 \mu\text{M}$  for Losartan against peptide-AMC (Table 1).

	Peptide (200 $\mu\text{M}$ )	Peptide $IC_{50}$ ( $\mu\text{M}$ )	ISG15 (200 $\mu\text{M}$ )	Ub (200 $\mu\text{M}$ )
Losartan	35.1% $\pm$ 2.7	1200 $\pm$ 61	6.9% $\pm$ 3.4	2.3% $\pm$ 1.4

Table 1. Percentile of inhibition and  $IC_{50}$  of cleavage of peptide-AMC, percentile of inhibition of ISG15-AMC and Ub-AMC in the presence of 200 $\mu\text{M}$  Losartan.  $IC_{50}$  of Losartan for cleavage of peptide-AMC is  $1200 \pm 61 \mu\text{M}$ .

ISG15 is the preferred substrate of SARS-CoV-2 PLpro [14]. To test the inhibitory effect, Losartan was tested against ISG15-AMC and peptide-AMC. At 200 $\mu\text{M}$ , Losartan is less effective at inhibiting cleavage of ISG15-AMC than against peptide-AMC. SARS-CoV-2 PLpro has a strong preference for ISG15 over peptide as a substrate displacing competitive inhibitors with lower affinity for ISG15. These data suggest that Losartan, along with its structure, may be interacting with the P3/P4 pocket of the PLpro [40]. This pocket is adjacent to the active site and facilitates cleavage of Ubl substrates by binding the C-terminal leucine and arginine of the RLRGG motif [41]. Other small molecule PLpro inhibitors of similar size have been shown to bind in this pocket in both SARS-CoV and SARS-CoV-2 [39].

**Efficacy of Losartan in Inhibiting SARS-CoV-2 PLpro.** To further explore the relationship between substrate affinity and inhibitor efficacy, Losartan was tested against Ub-AMC at 200 $\mu\text{M}$ . SARS-CoV-2 PLpro has a strong preference for ISG15 over Ub as a substrate [14], where the catalytic efficiency of the PLpro for Ub is approximately one-tenth that of ISG15 but more than 250 times that of the peptide-AMC. Therefore, competitive non-covalent inhibitors limit Ub-AMC cleavage at a rate somewhere between those of ISG15-AMC and peptide-AMC. Losartan had an inhibition rate of 2.3% when tested against Ub-AMC (table 1). Inhibition rate of Losartan was 6.9% against ISG15 cleavage (table 1). These differences between inhibitory rates of Losartan against ISG15-AMC and Ub-AMC are unlikely to have a qualitative difference in a biological system. However, to confirm this, molecular

weight shift assays were performed with more biologically accurate substrates (Fig. 1).

**Effect of Losartan on Tetra-Ub Deubiquitination.** Ubl substrates with AMC tags at their C-terminal glycine are not entirely reflective of natural substrates. PLpros have been observed to prefer cleaving poly-Ub chains over mono-Ub substrates [42, 43]. To determine if the inhibition values derived from AMC cleavage assays are reflective of a qualitative change in DUB and deISGylase activity, Losartan was tested against human proISG15 and K48 linked tetra-Ub. As expected, Losartan at 2 mM shows a small deISGylase activity relative to the control (Fig. 1). However, Losartan at 2.25 mM almost completely eliminated DUB activity (Fig.2).






Fig. 1. Gel shift analysis. Inhibitory activity of Losartan on deISGylation of PLpro. (a) deISGylation of PLpro on proISG15 in 10  $\mu$ M of proISG run against 20 nM of SARS-CoV-2 PLpro, at 37°C, over 2 hours with samples taken at the indicated intervals with Gel cleavage assay visualized by Commassie Blue Staining. Strong PLpro deISGylation is noted. (b) Losartan, at 2mM concentration added to proISG15 and PLpro solution, demonstrates insignificant inhibitory effect on PLpro deISGylation between 5 and 30 minutes.







*Fig. 2. Inhibitory effect of Losartan on deubiquitination activity of PLpro on K48-Ub<sub>4</sub> (a) At the mentioned intervals over 6 hours, multiple ten  $\mu$ L samples of Lys48 linked tetra Ub at 13.65  $\mu$ M with 23 nM SARS-CoV-2 PLpro in AMC buffer at 37 °C were taken and heat-shocked at 98 °C for 5 minutes. Gel cleavage assay visualized by Comassie Blue Staining shows PLpro's cleavage of Ub<sub>4</sub> to mostly DUB and some monoUb. (b) Addition of Losartan, at 2.25 mM concentration, demonstrates a significant inhibitory effect on PLpro deUbiquitination of Ub<sub>4</sub>.*

**Antiviral Activity of Losartan in Cell Culture.** Adding Losartan to Vero E6 cell cultures showed that dose-dependently (0-100 $\mu$ M concentrations), it could significantly ( $p < 0.001$ ) reduce cell destruction and cell replication as noted in 6-well and 96-well assays, respectively (Figures 3 and 4). This result was achieved in both pre- and post-infection groups in both of 6-well and 96-well setting. In 6-well assay, Losartan increasing concentrations reduced the number of plaques up to 70% and in 96-well assay the number of infected cells by up to 80% ( $p < 0.001$ ). The half maximal effective concentration ( $EC_{50}$ ) of Losartan in 96-well experiment significantly ( $p < 0.001$ ) decreased from 40.81  $\mu$ M in post-infection group to 13.65  $\mu$ M in the pre-infection group (Fig. 5).

### Effect of Losartan on Viral Replication of SARS-CoV-2 Infected Vero E6 Cells




Fig.3. Losartan, in a dose dependent manner, decreases virus induced cell destruction significantly ( $p<0.001$  with Wilcoxon test), i.e. the number of plaques, by better than 80%. Pre-infection and post-infection groups indicate that Losartan was added one hour before (pre-infection) and after the cells were infected (post-infection) with SARS-CoV-2, respectively.

### Effect of Losartan on Viral Replication of SARS-CoV-2 Infected Vero E6 Cells




Fig.4. Losartan, in a dose dependent manner, decreases the percentage of infected cells in pre-infection group more significantly than post-infection group (Wilcoxon test  $p<0.001$ ). Pre-infection and post-infection groups indicate that Losartan was added one hour before (pre-infection) and after the cells were infected (post-infection) with SARS-CoV-2, respectively.



## EC<sub>50</sub> of Losartan Inhibiting Viral Replication of SARS-CoV-2 in Infected Vero E6 Cells





Fig. 5. EC<sub>50</sub> curves in pre- and post-infection groups in 96-well assay. Losartan dose-dependently reduces the production of viral nuclear proteins in Vero E6 cells (near 80%). EC<sub>50</sub> curves are significantly different in pre- and post-infection groups, significantly ( $P < 0.001$ ).

### Discussion:

Replication of SARS-CoV-2 depends on PLpro and Mpro functions. Inhibitors of SARS-CoV PLpro, in several studies, have been shown to be as effective against SARS-CoV-2 PLpro [44, 45]. Although many of the findings were promising, the development in introducing effective drugs is lagging. In 2008, discovery of successful antivirals against SARS-CoV was paused after spread of the virus was contained. Discoveries in disease pathogenesis of SARS-CoV-2 can aid in discovery of novel treatments and drugs. One hypothesis proposes that dysregulation in renin-angiotensin system (RAS) components contribute to the cytokine storm in COVID-19. Downregulation of ACE2 during the entry of the virus into the host cells leads to an increase in angiotensin II/angiotensin(1-7) ratio with proinflammatory, pro-apoptotic, destructive and pro-thrombotic effects [27, 46]. In animal studies, it was shown that ACE2 deficiency in mice and infusion of Ang II in swine resulted in corneal inflammatory response and lung pathology, respectively, resembling exactly the immunopathological changes seen in COVID-19 [47, 48]. In an

in-silico study, Losartan was shown to change the tertiary structure of ACE2 in binding with receptor binding domain (RBD) of S protein of the virus as well as inducing modification in conformational shape of SARS-CoV-2 papain-like protease [27]. Accordingly, Losartan may attenuate the inflammatory response and improve organ dysfunctions associated with COVID-19 by rebalancing RAS components and possibly reducing viral affinity for ACE2. This ligand may inhibit the PLpro function as it poses on the same position as the PLpro inhibitor, GRL-0617, does (Fig. 6) [27].



*Fig.6. Positioning of GRL-0617 (PLpro inhibitor) and Losartan in the active site of PLpro. (a) X-ray crystallography structure of PLpro and GRL-0617 (PDB ID: 7cmd). (b) Losartan positioning was achieved after 100ns MD simulation. Losartan poses in the same position of the inhibitor (GRL-0617) according to PLpro amino acids in the circumferential area of these two ligands. Hydrogen bonding between nitrogen (N) in Losartan imidazole ring and sulfhydryl group of cysteine (C111) may inhibit initial phase of attacking of cysteine (C111) to the carbonyl group of the substrate in the general cleavage chemical reaction (Fig. 9). Note: X-ray crystallography in contrast to NMR analysis and theoretical modeling cannot resolve hydrogen atoms in most protein crystals found in PDB files [49].*

Our in vitro study revealed that Losartan was a weak inhibitor of PLpro in cleavage of peptide-AMC ( $IC_{50}=1200\pm 61\mu M$ ). It did not substantially suppress deISGylating ability of PLpro (Fig. 2). It is possible that Losartan interacts with the P3/P4 pocket of PLpro adjacent to its active site and is displaced in the presence of ISG15. This pocket could facilitate cleavage of Ubl substrates by binding the C-terminal of leucine and arginine, of the RLRGG motif, through a protonating reaction in a cleft in the PLpro containing a conserved triad of Histidine(H272)-Cysteine(C111)-Aspartic Acid(D286) in papain-like proteases [22, 24, 40]. This is in agreement with the previous bioinformatic findings showing a decrease in the affinity of Losartan for PLpro in the presence of UBI1 (Fig. 7, Fig. 8) [27].




Fig. 7. PLpro thumb-palm-finger structure and two positions of Losartan in docking with PLpro. Docking site 1 with -10.10 Kcal/mol energy is the preferred pose for Losartan in the absence of UBL1. Docking site 2 with -6.43 Kcal/mol energy indicates the preferred pose for Losartan in the presence of UBL1. This demonstrates the decrease in affinity of Losartan in docking with PLpro in the presence of UBL1. This is in concordance with the finding that UBL1 and ISG15 might dislocate Losartan as a competitive inhibitor.





Fig. 8. The interaction of SARS-CoV-2 papain-like protease with ISG15 and UBI1 after 100ns MD simulation. The cleavage site of PLpro comprises of a triad of Histidine(H272), Cysteine(C111) and Aspartic acid(D286). C-terminal LXGG of UBI1 and ISG15 are seen in the vicinity of the active site. PLpro crystal structure in interaction with ISG15 (a) was retrieved from protein data bank (PDB ID: 6yva) in which the active site contained Serine (S111) in place of Cysteine (C111) as a point mutation. To emulate the wild structure of PLpro, Serine was replaced by Cysteine and a run of 100ns MD simulation was performed with the new triad.

It has been reported that SARS-CoV-2 PLpro prefers deISGylation 10 times more than deubiquitination [14]. However, our study demonstrated that Losartan in 2.25mM

concentration could completely suppress cleavage of monoubiquitin molecules from polyubiquitin chains by PLpro (Fig.1, Fig. 2).

Active (cleavage) site of PLpro with its canonical thumb-palm-finger like structure (Fig. 7), similar to other cysteine proteases in Coronaviruses, comprises two amino acids, histidine and cysteine, to which aspartic acid is added in the case of SARS-CoV and SARS-CoV-2 [22]. The maximum rate of papain-catalyzing activity occurs in pH of 6.2 where both imidazolium ion ( $\text{ImH}^+$ ) (protonated form of imidazole ring) of histidine and thiolate (deprotonated) form of sulfhydryl group of cysteine are available [50]. Assuming that intracellular pH is near 7 and drops in the context of intracellular ROS overproduction in inflammations like what happens in COVID-19 [27, 51], active site of PLpro finds a favorable milieu to cleave nsps efficiently. As a general catalytic reaction, papain-like protease thiolate ion of cysteine produces a tetrahedral intermediate by attacking the carbonyl group of the substrate which is then released through protonation by  $\text{ImH}^+$  (Fig. 9) [50].




*Fig. 9. General chemical reaction in cleavage of the carboxy terminal of substrates of PLpro. While cysteine attacks the carbonyl group of a substrate polypeptide and produces an acyl-enzyme intermediate, relaying of proton through imidazole ring of histidine with supporting protonating activity of aspartic acid (D286) in case of PLpro and with the aid of a water molecule in case of Mpro, releases the substrate from cysteine and the triad once again resumes its active configuration. According to our 100ns bioinformatic analysis, nitrogen in imidazole ring of Losartan through protonation of sulfhydryl group of cysteine likely impedes production of tetrahedral intermediate.*

A MD analysis [52] revealed that tertiary structure and folding of PLpro in its cleavage cleft changes cysteine (C111) and histidine (H272) to negatively charged deprotonated cysteine and positively charged doubly protonated histidine, respectively. In this context, negatively charged aspartic acid (D286) aids in stabilization of positively charged




histidine (H272) [52]. In fact, imidazole ring is a unique structure in biologic reactions, which by possessing two identical nitrogen atoms, it is responsible for relaying protons from one site to another. If two imidazole rings present closely in the path of proton transfer ( $\text{ImH}^+ \dots \text{Im}$ ) an energy barrier may impede the journey of the protons [53]. Accordingly, changes in pH and electrical charge in the catalytic triad of PLpro or presence of any impedance against protonation in the cleavage reaction may distort hydrogen bonds and reduce catalytic efficiency of PLpro in cleavage of nsp1/nsp2, nsp2/nsp3 and nsp3/nsp4 which occurs in c-terminal end of nsp1, nsp2 and nsp3. Losartan approaches the triad with its imidazole ring which may compete and impede proton transfer in making hydrogen bond with the imidazole ring of histidine (Fig. 10). It is notable that the active site of Mpro of SARS-CoV-2 is composed of a dyad of histidine (H41) and cysteine (C145) to which a water molecule instead of aspartic acid aids in protonation of histidine (H41) [54]. This dyad contributes to cleavage of nsps through the same chemical reaction seen in Figure 9. Also, imidazole ring of Losartan may disrupt the interaction of histidine and cysteine in this protease.



*Fig. 10. Losartan positioning in the active site of PLpro after 100ns MD simulation. Imidazole ring of Losartan competes with imidazole ring of histidine (H272) for hydrogen bonding with cysteine (C111) in the cleavage triad. Gromacs 2018 package was used for optimization of PLpro (PDB ID: 6xaa) and running 100ns MD simulation through forcefield gromos.*

A prior MD analysis [27] demonstrated that Losartan changes the conformational shape of SARS-CoV-2 PLpro. In this study, RMSD graph of 100ns MD simulation of PLpro with and without Losartan shows the changes in the shape of PLpro after 80 ns (Fig. 11) [27].



*Fig. 11. Superimposition of RMSD graphs of 100ns MD simulation of PLpro with (red) and without (green) Losartan. Conformational shape of PLpro changes reasonably after 80ns (black arrow).*

Despite the above-mentioned findings in MD simulation, Losartan, in our in vitro study, showed only weak inhibitory effect on PLpro cleavage of monoubiquitin from polyubiquitin chain and only minor inhibition of deISGylation. As to the fact that ubiquitin and ISG15 do not show any homology with at least nsp2 amino acid sequence, it might be likely that cleavage of nsps by PLpro through the general chemical reaction in the active site (Fig. 9) might be associated with different positioning of nsps in PLpro in comparison with ubiquitin and ISG15. Thus, Losartan by penetrating the active site and altering hydrogen bonds in the three effector residues may interfere with cleavage of nsps. Though, this assumption needs further investigation, as an evidence for this concept, our in vitro study showed that 200uM concentration of Losartan could inhibit the cleavage of peptide-AMC containing RLRGG C-terminal sequence up to  $35.1\% \pm 2.7$  while at the same concentration, this compound could only inhibit cleavage of ISG15 and UBI1 at  $6.9\% \pm 3.4$  and  $2.3\% \pm 1.4$ , respectively (table 1).

Considering the putative effects of Losartan on Ang II/angiotensin(1-7) ratio, and on ACE2 in interaction with SARS-CoV-2 RBD, PLpro and Mpro, we tested the effect of Losartan on cell destruction and replication by SARS-CoV2 in Vero E6 cell culture.

Vero E6 cells derived from the kidney of African green monkeys, strongly express ACE2 on their apical membranes as observed in certain cells of the respiratory tract [55-57]. Additionally, these cells do not produce type I interferons (IFN type I) allowing SARS-CoV and SARS-CoV-2 replication without being recognized by cell innate immunity [58-63]. According to the results of our Vero E6 cell culture study, which was performed in two-series of triplicated tests, Losartan showed cell protection in both pre- and post-infection groups in a dose dependent manner ( $p < 0.001$ ). Results of clinical trials are expected to be better than *in vitro* results as Vero E6 cells lack interferon producing ability.

Cell destruction in 6-well (number of plaques) and percent of infected cells in 96-well (cells containing nuclear protein) were both reduced significantly ( $p < 0.001$ ) when Losartan was added in increasing concentrations from 0  $\mu\text{M}$  to 100  $\mu\text{M}$  by 80% in pre-infection and 70% in post-infection groups (Figures 3 and 4). Based on  $\text{EC}_{50}$ , Losartan when used prior to infecting the cells (pre-infection group) with SARS-CoV-2, reduced NP production by over 50% more than when it is added to the cell culture after infecting the cells with the virus. Therefore, prophylactic use of Losartan may have a significant ( $p < 0.001$ ) clinical benefit if validated by future relevant clinical trials. Additionally,  $\text{EC}_{50}$  for GRL-0617, a noncovalent inhibitor of PLpro, is reported to be about 27.6  $\mu\text{M}$  [14]. Losartan with  $\text{EC}_{50}$  of 7.29  $\mu\text{M}$  in plaque reduction experiment may be more efficient when compared to GRL-0617 in prevention of SARS-CoV2 pathogenesis.

The prominent effect of Losartan in pre-infection group is in agreement with a previously published MD analysis revealing a lower affinity of the virus for ACE2 in the presence of Losartan [27]. Furthermore, the cell surviving potential of Losartan might likely be an evidence supporting the previous bioinformatic finding that this drug could change the conformational shape of PLpro or interfere with the interaction of functional residues (histidine, cysteine) in PLpro or Mpro of the virus [27].

In previous studies, Losartan was described to have anti-inflammatory, anti-apoptotic and anti-thrombotic effects through downregulating Ang II mediated AT1R stimulation [27, 64-71]. Entry of SARS-CoV-2 is associated with downregulation of ACE2 and a



subsequent acute rise in Ang II/angiotensin (1-7) ratio with pro-inflammatory, pro-apoptotic, and prothrombotic outcomes [72-75]. In order to control SARS-CoV-2-induced inflammatory responses, many experts have been trying to extend the half-life of ACE2, given the protective role of ACE2 in COVID-19 [76]. As an alternate to restoring ACE2, Losartan, which rebalances the dysregulated RAS in COVID-19, may attenuate ARDS in patients with COVID-19 [27]. Series of unpublished clinical observations revealed the ability of Losartan in suppressing lung inflammation in this disease. Clinical trials are underway to assess efficacy of Losartan in treatment of COVID-19. Data from clinical trial combined with the data from this study may improve the management of this deadly disease.

## **Conclusion:**

COVID-19 has resulted in widespread social, economic, and healthcare crisis. Addition of effective antiviral successful vaccination and antiviral treatment strategy against SARS-CoV-2 would greatly aid in the control of this pandemic. Losartan in this study showed weak inhibitory effect on viral PLpro deubiquitinase and delSGylase properties. This study also showed that Losartan added to the cell culture of Vero E6 cells prior to and after infection of the cells with SARS-CoV2 can inhibit SARS-CoV-2 cell destruction and replication. This, if validated by ongoing clinical trials in different continents, may mean that Losartan has both prophylactic and therapeutic effects in the treatment of COVID-19. Additional experiments are needed to better assess the structural changes in the viral proteins and their biological products when exposed to Losartan. Outcome of these experiments may provide a viable pathway for antiviral design and development. If validated in clinical trials, Losartan with its inhibitory effect on viral replication and its significant benefits in cell protection without any cell toxicity may play an important role in slowing the spread of the disease, medical management of individuals unresponsive to vaccination or new mutations, easing healthcare cost and burden in communities globally.

## **Methods:**

### **Chemicals and Reagents.**

Z-RLRGG-7-amino-4-methyl-courmarin (peptide-AMC) was purchased from Bachem. Ubiquitin-7-amino-4-methylcourmarin (Ub-AMC) was purchased from Boston Biochem; human ISG15-7-amino-4-methylcourmarin (ISG15-AMC) was purchased from Boston Biochem. Lys48 linked tetra-Ub were obtained from Boston Biochem; DL-dithiothreitol (DTT) was purchased from GoldBio, and isopropyl- $\beta$ -D-thiogalactopyranoside (IPTG) was purchased from GoldBio. 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) was purchased from Fisher BioReagents. Imidazole was purchased from Acros Organics; tris(hydroxymethyl)aminomethane (Tris) was purchased from Fisher Scientific. Losartan and Sodium chloride (NaCl) were purchased from Fisher Chemical, and bovine serum albumin (BSA) was purchased from Sigma Life Science.

### **Determination of IC<sub>50</sub> Values**

IC<sub>50</sub> assays were performed using methods previously described for peptide-AMC cleavage experiments [45]. All assays were run using Corning Costar half-volume 96-well plates containing AMC buffer (100mM NaCl, 50mM HEPES [pH = 7.5], 0.01mg/mL bovine serum albumin (BSA), and 5mM DTT) to a final volume of 50 $\mu$ L and performed in triplicate. The CLAIROstar plate reader (BMG Lab Tech, Inc.) was used to measure the fluorescence of the AMC cleavage, and the data was analyzed using MARS (BMG Lab Tech, Inc.). Assays using peptide-AMC substrate contained 1 $\mu$ M SARS-CoV-2 PLpro and 50 $\mu$ M peptide-AMC in 98% AMC buffer/2% DMSO. Reactions were performed in triplicate with inhibitor concentrations ranging from 390nM to 2.25mM. Further assays utilizing ISG15-AMC and Ub-AMC contained 1nM PLpro with 1 $\mu$ M substrate or 25nM PLpro with 2 $\mu$ M substrate respectively. IC<sub>50</sub> calculations were performed using Prism8 from GraphPad.

### **Inhibition of Poly-Ub and proISG15 Cleavage**

Lys48 linked tetra-Ub obtained from Boston Biochem was incubated at 10.5 $\mu$ M with 23nM SARS-CoV-2 PLpro and 2.25mM Losartan. Reactions were performed in 97.75% AMC buffer/2.25% DMSO at a volume of 80 $\mu$ L and a temperature of 37°C. 10 $\mu$ L samples were taken at the indicated time points and heat-shocked at 98°C for 5 min. SDS-PAGE analysis was performed using Mini-PROTEAN TGX and Coomassie blue.

Utilizing similar parameters 10 $\mu$ M human proISG15 was incubated with 20nM PLpro and 2mM Losartan. Reactions were performed in 98% AMC buffer/2% DMSO at a volume of 90 $\mu$ L. 10 $\mu$ L samples were taken at the indicated time points and heat-shocked at 98°C for 5 min. SDS-PAGE analysis was performed using Mini-PROTEAN TGX Stain-Free.

### **6-Well and 96-Well Losartan Antiviral Assays.**

In the 6-well setting, plaques represent the destructed cells, while in the 96-well test the percentage of Relative Light Unit (RLU) represents detection of viral nuclear protein (NP) in the infected cells.

### **SARS-CoV-2 Post-infection Cells and Losartan Antiviral Assays.**

SARS-CoV-2 (2019-nCoV/USA-WA1/2020; MN985325.1) was received from BEI resources and propagated in Vero E6. Infections were done at a multiplicity of infection (MOI) of 0.1 in serum-free in Dulbecco's minimal essential medium (DMEM) for 1h after which the virus-containing media was decanted and replaced with DMEM supplemented with 1% heat-inactivated fetal bovine serum [77]. The virus was propagated for 72 hours before it was harvested and the titer determined by plaque assay on Vero E6 cells [78]. The viral plaques were counted and the titer was determined as PFU/ml. The Vero cells were plated at 5 x 10<sup>5</sup> cells/well in a 6-well plate and incubated overnight at 37°C. The following day the Losartan was prepared into the following concentrations/well in a separate plate; 100  $\mu$ M, 50  $\mu$ M, 25  $\mu$ M, 12  $\mu$ M, 6  $\mu$ M, 3  $\mu$ M and 1  $\mu$ M. The cells were washed once with PBS once and then infected at a multiplicity of infection (MOI) of 0.01 for 1h after which the virus containing media was removed and the Losartan concentrations were added to the cells with 3 mL overlay and incubated for 96 hours at 37°C at 5% CO<sub>2</sub>. The cells were then fixed and stained with crystal violet to determine plaque numbers. These were all done in triplicate and the calculations were performed using Prism8 from GraphPad. In the 96-well assay, 200  $\mu$ L of the media containing the Losartan concentrates and the virus was incubated for 96 hours, in triplicate. This mixture was fixed, stained for Viral nuclear protein (NP), and assay on Cellomics arrays was performed. Relative Light Unit (RLU) detecting viral NP correlates with replication the

infected cells [79]. Average percentage responder intensity of the fluorescent channel from NPs of the virus was measured and the calculations were performed using Prism8 from GraphPad.

### **SARS-CoV-2 Pre-infection Cells and Losartan Antiviral Assays.**

SARS-CoV-2 (2019-nCoV/USA-WA1/2020; MN985325.1) was received from BEI resources and propagated in Vero E6. Infections were done at a multiplicity of infection (MOI) of 0.1 in serum-free in Dulbecco's minimal essential medium (DMEM) for 1h after which the virus-containing media was decanted and replaced with DMEM supplemented with 1% heat-inactivated fetal bovine serum [77]. The virus was propagated for 72 hours before it was harvested and the titer determined by plaque assay on Vero E6 cells [78]. The viral plaques were counted and the titer was determined as PFU/ml. The Vero cells were plated at  $5 \times 10^5$  cells/well in a 6-well plate and incubated overnight at 37°C. The cells were washed once with PBS once. Losartan was prepared into the following concentrations/well in a separate plate; 100 µM, 50 µM, 25 µM, 12 µM, 6 µM, 3 µM and 1 µM. For a total of 3 mL final volume per well, Losartan concentrate were added to the Vero E6 wells and incubated for one hour. Viral dilution was then made at a multiplicity of infection (MOI) of 0.01 after which the virus containing media was removed and the Losartan concentrations were added to the cells with 3 mL overlay and incubated for 96 hours at 37°C at 5% CO<sub>2</sub>. The cells were then fixed and stained with crystal violet to determine plaque numbers. These were all done in triplicate and the calculations were performed using Prism8 from GraphPad. In the 96-well assay, 200 µL of the media containing the Losartan concentrates and the virus was incubated, in triplicate. This mixture was fixed, stained for Viral NP, and assay on Cellomics arrays was performed. Relative Light Unit (RLU) detecting viral nuclear protein (NP) correlates with viral replication in the infected cells [79]. Average percentage responder intensity of the fluorescent channel from NPs of the virus was measured and the calculations were performed using Prism8 from GraphPad.

### **Author Contributions**

The manuscript was written through the contributions of all authors. All authors have approved the final version of the manuscript.

## Acknowledgments:

We thank our families and friends for their support which provided us with the time to pursue this endeavor while they endured the challenges that all families have encountered in this pandemic.

The humanitarian research in this article was made possible by the University of Georgia College of Pharmacy, Office of Research, College of Veterinary Medicine, and the University of Georgia's Center for Drug Discovery (S.D.P).

We thank Derren Barken, PhD for helping with verification of our statistical analysis of the data presented in this research.

We thank California Medical Innovations Institute for their reception and encouragement.

## References:

1. Chan, J.F.-W., et al., *Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan*. *Emerging microbes & infections*, 2020. **9**(1): p. 221-236.
2. Gorbalenya, A., et al., *The species severe acute respiratory syndrome related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2*. *Nat Microbiol* 5: 536–544. 2020.
3. Rossi, G.A., et al., *Differences and similarities between SARS-CoV and SARS-CoV-2: spike receptor-binding domain recognition and host cell infection with support of cellular serine proteases*. *Infection*, 2020: p. 1-5.
4. Lu, R., et al., *Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding*. *The Lancet*, 2020. **395**(10224): p. 565-574.
5. Ou, X., et al., *Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV*. *Nature communications*, 2020. **11**(1): p. 1-12.
6. Huang, Y., et al., *Structural and functional properties of SARS-CoV-2 spike protein: potential antiviral drug development for COVID-19*. *Acta Pharmacologica Sinica*, 2020. **41**(9): p. 1141-1149.
7. Fehr, A.R. and S. Perlman, *Coronaviruses: an overview of their replication and pathogenesis*, in *Coronaviruses*. 2015, Springer. p. 1-23.
8. Helmy, Y.A., et al., *The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control*. *Journal of Clinical Medicine*, 2020. **9**(4): p. 1225.
9. Snijder, E., E. Decroly, and J. Ziebuhr, *The nonstructural proteins directing coronavirus RNA synthesis and processing*, in *Advances in virus research*. 2016, Elsevier. p. 59-126.
10. Astuti, I., *Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response*. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, 2020.
11. Wu, J., et al., *Severe acute respiratory syndrome Coronavirus 2: from gene structure to pathogenic mechanisms and potential therapy*. *Frontiers in microbiology*, 2020. **11**.

12. Wu, Y., et al., *Main protease of SARS-CoV-2 serves as a bifunctional molecule in restricting type I interferon antiviral signaling*. Signal transduction and targeted therapy, 2020. **5**(1): p. 1-3.
13. Shin, D., et al., *Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity*. Nature, 2020: p. 1-6.
14. Freitas, B.T., et al., *Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-like protease*. ACS Infectious Diseases, 2020. **6**: p. 2099-2109.
15. Nejat, R. and A.S. Sadr, *SARS Virus Papain-like Protease: A Mysterious Weapon*. Journal of Biostatistics and Epidemiology, 2019. **5**(4): p. 288-295.
16. Mielech, A.M., et al., *Nidovirus papain-like proteases: multifunctional enzymes with protease, deubiquitinating and deISGylating activities*. Virus research, 2014. **194**: p. 184-190.
17. Lei, X., et al., *Activation and evasion of type I interferon responses by SARS-CoV-2*. Nature communications, 2020. **11**(1): p. 1-12.
18. Matthews, K., et al., *The SARS coronavirus papain like protease can inhibit IRF3 at a post activation step that requires deubiquitination activity*. Virology journal, 2014. **11**(1): p. 209.
19. Li, S.-W., et al., *SARS coronavirus papain-like protease inhibits the TLR7 signaling pathway through removing Lys63-linked polyubiquitination of TRAF3 and TRAF6*. International journal of molecular sciences, 2016. **17**(5): p. 678.
20. Sun, L., et al., *Coronavirus papain-like proteases negatively regulate antiviral innate immune response through disruption of STING-mediated signaling*. PloS one, 2012. **7**(2): p. e30802.
21. Lowe, E.L., et al., *Ubiquitination and de-ubiquitination: role in regulation of signaling by Toll-like receptors*. Journal of endotoxin research, 2006. **12**(6): p. 337-345.
22. Ratia, K., et al., *Coronavirus Papain-like Peptidases*. 3 ed. Handbook of Proteolytic Enzymes. Vol. 2. 2013: Academic Press. 2195-2199.
23. Ratia, K., et al., *Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme*. Proceedings of the National Academy of Sciences, 2006. **103**(15): p. 5717-5722.
24. Gao, X., et al., *Crystal structure of SARS-CoV-2 papain-like protease*. Acta Pharmaceutica Sinica B, 2020: p. 1-9.
25. Phadke, M. and S. Saunik, *Use of angiotensin receptor blockers such as Telmisartan, Losartan in nCoV Wuhan Corona Virus infections-Novel mode of treatment*. British Medical Journal, 2020. **2020**,**368**:m406.
26. Sun, M., et al., *Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia*. Zhonghua jie he he hu xi za zhi= Zhonghua jiehe he huxi zazhi= Chinese journal of tuberculosis and respiratory diseases, 2020. **43**: p. E014-E014.
27. Nejat, R. and A.S. Sadr, *Are Losartan and Imatinib Effective Against SARS-CoV2 Pathogenesis? A Pathophysiologic-Based In Silico Study*. In Silico Pharmacology, 2021. **9**(1): p. 1.
28. Vaduganathan, M., et al., *Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19*. New England Journal of Medicine, 2020. **382**(17): p. 1653-1659.
29. Guo, J., et al., *Coronavirus disease 2019 (covid-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection*. Journal of the American Heart Association, 2020. **9**(7): p. e016219.
30. Otero, D.L., et al., *Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population*. CARDIOVID registry. Revista Española de Cardiología (English Edition), 2020.
31. Koshy, A., et al., *Renin-angiotensin system inhibition and risk of infection and mortality in COVID-19: a systematic review and meta-analysis*. Internal Medicine Journal, 2020.



32. Mielech, A.M., et al., *Murine Coronavirus Ubiquitin-Like Domain Is Important for Papain-Like Protease Stability and Viral Pathogenesis*. Journal of Virology, 2015. **89**(9): p. 4907.
33. Frieman, M., et al., *Severe Acute Respiratory Syndrome Coronavirus Papain-Like Protease Ubiquitin-Like Domain and Catalytic Domain Regulate Antagonism of IRF3 and NF- $\kappa$ B Signaling*. Journal of Virology, 2009. **83**(13): p. 6689.
34. Devaraj, S.G., et al., *Regulation of IRF-3-dependent Innate Immunity by the Papain-like Protease Domain of the Severe Acute Respiratory Syndrome Coronavirus*. Journal of Biological Chemistry, 2007. **282**(44): p. 32208-32221.
35. Bailey-Elkin, B.A., et al., *Crystal structure of the Middle East respiratory syndrome coronavirus (MERS-CoV) papain-like protease bound to ubiquitin facilitates targeted disruption of deubiquitinating activity to demonstrate its role in innate immune suppression*. J Biol Chem, 2014. **289**(50): p. 34667-82.
36. Armstrong, L., et al., *Characterization of protease activity of Nsp3 from SARS-CoV-2 and its in vitro inhibition by nanobodies*. bioRxiv, 2020.
37. Lei, J., Y. Kusov, and R. Hilgenfeld, *Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein*. Antiviral research, 2018. **149**: p. 58-74.
38. Lindner, H.A., et al., *The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme*. Journal of virology, 2005. **79**(24): p. 15199-15208.
39. Ratia, K., et al., *A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication*. Proceedings of the National Academy of Sciences of the United States of America, 2008. **105**: p. 16119-24.
40. Báez-Santos, Y.M., S.E.S. John, and A.D. Mesecar, *The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds*. Antiviral research, 2015. **115**: p. 21-38.
41. Kong, L., et al., *Structural view and substrate specificity of papain-like protease from avian infectious bronchitis virus*. The Journal of biological chemistry, 2015. **290**(11): p. 7160-7168.
42. Capodagli, G.C., et al., *Diversity of ubiquitin and ISG15 specificity among nairoviruses' viral ovarian tumor domain proteases*. Journal of virology, 2013. **87**(7): p. 3815-3827.
43. Dzimianski, J.V., et al., *Probing the impact of nairovirus genomic diversity on viral ovarian tumor domain protease (vOTU) structure and deubiquitinase activity*. PLoS pathogens, 2019. **15**(1): p. e1007515.
44. Hosseini-Zare, M.S., R. Thilagavathi, and C. Selvam, *Targeting severe acute respiratory syndrome-coronavirus (SARS-CoV-1) with structurally diverse inhibitors: a comprehensive review*. RSC Advances, 2020. **10**(47): p. 28287-28299.
45. Ratia, K., et al., *A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication*. Proceedings of the National Academy of Sciences, 2008. **105**(42): p. 16119-16124.
46. Miesbach, W., *Pathological role of angiotensin II in severe COVID-19*. TH open: companion journal to thrombosis and haemostasis, 2020. **4**(2): p. e138.
47. Wang, J., et al., *The ACE2-deficient mouse: A model for a cytokine storm-driven inflammation*. The FASEB Journal, 2020. **34**(8): p. 10505-10515.
48. Rysz, S., J. Al-Saadi, and M. Farm, *COVID-19 pathophysiology may be driven by a loss of inhibition of the renin-angiotensin-aldosterone system*. PREPRINT (Version 2) available at Research Square, 2020. **10**.
49. Creighton, T.E., *Proteins: structures and molecular properties*. 1993: Macmillan.
50. Rawn, J.D. and R.J. Ouellette, *Amino acids, Peptides and Proteins*. Organic Chemistry: Structure, Mechanism, Synthesis. 2018: Academic Press. 929-971.



51. Clément, M.-V. and S. Pervaiz, *Intracellular superoxide and hydrogen peroxide concentrations: a critical balance that determines survival or death*. Redox Report, 2001. **6**(4): p. 211-214.
52. Henderson, J.A., et al., *Assessment of proton-coupled conformational dynamics of SARS and MERS coronavirus papain-like proteases: Implication for designing broad-spectrum antiviral inhibitors*. The Journal of chemical physics, 2020. **153**(11): p. 115101.
53. Scheiner, S. and M. Yi, *Proton transfer properties of imidazole*. The Journal of Physical Chemistry, 1996. **100**(22): p. 9235-9241.
54. Pillaiyar, T., et al., *An overview of severe acute respiratory syndrome–coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy*. Journal of medicinal chemistry, 2016. **59**(14): p. 6595-6628.
55. Ren, X., et al., *Analysis of ACE2 in polarized epithelial cells: surface expression and function as receptor for severe acute respiratory syndrome-associated coronavirus*. Journal of general virology, 2006. **87**(6): p. 1691-1695.
56. Ammerman, N.C., M. Beier-Sexton, and A.F. Azad, *Growth and maintenance of Vero cell lines*. Current protocols in microbiology, 2008. **11**(1): p. A. 4E. 1-A. 4E. 7.
57. Todd, K.V. and R.A. Tripp, *Vero Cells as a Mammalian Cell Substrate for Human Norovirus*. Viruses, 2020. **12**(4): p. 439.
58. Stoltz, M. and J. Klingström, *Alpha/beta interferon (IFN- $\alpha/\beta$ )-independent induction of IFN- $\lambda$ 1 (interleukin-29) in response to Hantaan virus infection*. Journal of virology, 2010. **84**(18): p. 9140-9148.
59. Desmyter, J., J.L. Melnick, and W.E. Rawls, *Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero)*. Journal of virology, 1968. **2**(10): p. 955-961.
60. Ng, M.-L., et al., *Proliferative growth of SARS coronavirus in Vero E6 cells*. Journal of General Virology, 2003. **84**(12): p. 3291-3303.
61. Ogando, N., et al., *SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology*, in bioRxiv. 2020.
62. Cox, R.M., J.D. Wolf, and R.K. Plemper, *Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets*. Nature microbiology, 2020: p. 1-8.
63. Yoon, J.-J., et al., *Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses*. Antimicrobial agents and chemotherapy, 2018. **62**(8).
64. Merino, A., et al., *Losartan prevents the development of the pro-inflammatory monocytes CD14+ CD16+ in haemodialysis patients*. Nephrology Dialysis Transplantation, 2012. **27**(7): p. 2907-2912.
65. Wang, X., et al., *Losartan suppresses the inflammatory response in collagen-induced arthritis by inhibiting the MAPK and NF- $\kappa$ B pathways in B and T cells*. Inflammopharmacology, 2019. **27**(3): p. 487-502.
66. Sukanuma, E., et al., *Losartan attenuates the coronary perivasculitis through its local and systemic anti-inflammatory properties in a murine model of Kawasaki disease*. Pediatric research, 2017. **81**(4): p. 593-600.
67. Tunçdemir, M., et al., *Antiapoptotic effect of angiotensin-II type-1 receptor blockade in renal tubular cells of hyperoxaluric rats*. Urological research, 2010. **38**(2): p. 71-80.
68. Yamada, K., T. Hirayama, and Y. Hasegawa, *Antiplatelet effect of losartan and telmisartan in patients with ischemic stroke*. Journal of Stroke and Cerebrovascular Diseases, 2007. **16**(5): p. 225-231.

69. Sakamoto, T., et al., *Antithrombotic effects of losartan in patients with hypertension complicated by atrial fibrillation: 4A (Angiotensin II Antagonist of platelet Aggregation in patients with Atrial fibrillation), a pilot study*. Hypertension Research, 2014. **37**(6): p. 513-518.
70. Silveira, K.D., et al., *Mechanisms of the anti-inflammatory actions of the angiotensin type 1 receptor antagonist losartan in experimental models of arthritis*. Peptides, 2013. **46**: p. 53-63.
71. Singh, B., et al., *Protective effect of losartan and ramipril against stress induced insulin resistance and related complications: Anti-inflammatory mechanisms*. European Journal of Pharmacology, 2017. **801**: p. 54-61.
72. Benigni, A., P. Cassis, and G. Remuzzi, *Angiotensin II revisited: new roles in inflammation, immunology and aging*. EMBO molecular medicine, 2010. **2**(7): p. 247-257.
73. Dandona, P., et al., *Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade*. Journal of human hypertension, 2007. **21**(1): p. 20-27.
74. Ciulla, M.M., *SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs/ARBs*. Hypertension Research, 2020: p. 1-2.
75. Banu, N., et al., *Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications*. Life Sciences, 2020: p. 117905.
76. Iwanaga, N., et al., *Novel ACE2-IgG1 fusions with improved activity against SARS-CoV2*. bioRxiv, 2020.
77. Harcourt, J., et al., *Severe acute respiratory syndrome coronavirus 2 from patient with coronavirus disease, United States*. Emerging infectious diseases, 2020. **26**(6): p. 1266.
78. Xu, J., Y. Zhang, and J.V. Williams, *Development and optimization of a direct plaque assay for trypsin-dependent human metapneumovirus strains*. Journal of virological methods, 2018. **259**: p. 1-9.
79. Bakre, A., et al., *Identification of host kinase genes required for influenza virus replication and the regulatory role of microRNAs*. PloS one, 2013. **8**(6): p. e66796.